Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients

The antisense oligonucleotide Nusinersen has been recently licensed to treat spinal muscular atrophy (SMA). Since SMA type 3 is characterized by variable phenotype and milder progression, biomarkers of early treatment response are urgently needed. We investigated the cerebrospinal fluid (CSF) concen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cell Mol Med
Main Authors: Faravelli, Irene, Meneri, Megi, Saccomanno, Domenica, Velardo, Daniele, Abati, Elena, Gagliardi, Delia, Parente, Valeria, Petrozzi, Lucia, Ronchi, Dario, Stocchetti, Nino, Calderini, Edoardo, D’Angelo, Grazia, Chidini, Giovanna, Prandi, Edi, Ricci, Giulia, Siciliano, Gabriele, Bresolin, Nereo, Comi, Giacomo Pietro, Corti, Stefania, Magri, Francesca, Govoni, Alessandra
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7077557/
https://ncbi.nlm.nih.gov/pubmed/32032473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14939
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados